The health care system is heavily burdened by obesity and associated comorbidities. The use of orlistate medication can reduce obesity morbidity and mortality but must be used in a wise manner. You can find more info here.
Orlistat is helpful to reduce body weight. BMI, cholesterol levels and waist circumference. A small drop in blood pressure and better glycemic control have also been seen in diabetic patients. The most prevalent cause of discontinuation is gastrointestinal side effects. The medicine can be utilized for achieving weight reduction objectives and reducing the consequences of obesity in the proper therapeutic context.
The support offered
The health care professional is required to support the medical team in informing the patient about the anticipated gastrointestinal effects of the medication. A pharmacist specializing in this medicine is important to maximizing treatment. The pharmacist has to help the medical team alter the amount or timing of other drugs to ensure the efficacy of the patient is not diminished. To reduce bad effects, the pharmacist must inform the patient on a good dose, timing, and frequency of therapy. Patient treatment by dieticians should ensure that the patient gets instructions for a balanced and reduced-calorie diet in terms of nutrition.
The efficacy of orlistat treatment can be improved by a coordinated and collaborative interprofessional team that achieves optimum outcomes.
Bodyweight, BMI, the circumference of the tail, and lipid profile must be monitored for orlistat patients. The levels of cyclosporine, anti-epileptics, and HIV virus need to be monitored when used with orlistat.
The orlistat overdose is not specific. If an overdose of orlistat is substantial, the patient should go promptly to an emergency room to receive assistance for 24 hours.
Interactions between medicines
Antiepileptics: Lipophile antiepileptics such as lamotrigine, valproate, vigabatrin, and gabapentin may decrease in absorption and hence reduce plasma levels. Anti-epileptic drug levels should be monitored in such instances.
Amiodarone: the absorption of amiodarone may be reduced by Orlistat.
Cyclosporine: Orlistat may also inhibit cyclosporine absorption (immunosuppressant), so that the two medicines are given with a gap of at least two hours. In individuals who are on orlistat, cyclosporine levels need to be monitored.
Levothyroxine: Orlistat may bind to levothyroxine in the intestines and limit its absorption, which leads to lower levothyroxine plasma levels and hypothyroidism. Clinicians should thus be advised to take at least 4 hours apart of levothyroxine and orlistat.
Warfarin: Orlistat along with warfarin might lead to extended INR and prothrombin time since orlistat decreases vitamin K absorption. Therefore, in patients who take these two treatments simultaneously, coagulation levels require monitoring. If the patient skips food, the dose of orlistat may be omitted. If the orlistat dosage was missed and more than 2 hours after the fat meal, the pill may be omitted since most of the fat absorption has happened and the medicine would not act well at that time.
Antiretroviral medicine: Orlistat also decreases antiretroviral drug uptake; HIV viral load monitoring is required. As orlistat lowers fat-soluble vitamin absorption, people should also take multivitamin supplements once day but should be given more than 2 hours after orlistat. You can check more from https://www.cmoapi.com/our-products/tadalafil/.